Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial

Study Title and Clinical Context

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial

This article summarizes a prespecified subgroup analysis from the VESALIUS-CV trial, focused on people who had previously undergone percutaneous coronary intervention (PCI) but had never had a myocardial infarction (MI, or heart attack). PCI includes procedures such as balloon angioplasty and stent placement, which are used to open narrowed coronary arteries. Although these patients have documented coronary artery disease, it has not been fully clear whether very intensive LDL-C lowering with evolocumab meaningfully reduces future cardiovascular events in this specific group.